Sixty Degrees Pharmaceuticals

Contributing Author

Recent Articles by Sixty Degrees Pharmaceuticals

Sep-03	60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference SXTP GlobeNewswire
Aug-14	60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results SXTP SXTP -9.62% GlobeNewswire
Jul-30	60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules SXTP -16.11% SXTP -6.40% GlobeNewswire
Jul-29	60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 SXTP GlobeNewswire
Jul-08	60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases SXTP GlobeNewswire
Jul-01	60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue SXTP GlobeNewswire
Jun-11	60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement SXTP GlobeNewswire
May-26	60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis SXTP GlobeNewswire
May-15	60 Degrees Pharmaceuticals Announces First Quarter 2026 Results SXTP GlobeNewswire
Apr-15	60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website SXTP -11.71% GlobeNewswire
Mar-31	60 Degrees Pharmaceuticals Announces 2025 Annual Results SXTP +15.89% GlobeNewswire
Mar-18	60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract SXTP -5.78% GlobeNewswire
Mar-11	60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial SXTP +71.28% GlobeNewswire
Feb-02	60 Degrees Pharmaceuticals Expands Access to ARAKODA with GoodRx Partnership SXTP -12.29% GlobeNewswire
Jan-28	60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use SXTP +7.88% GlobeNewswire
Jan-22	60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA for Malaria Prevention SXTP +152.00% GlobeNewswire
Jan-15	60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio SXTP GlobeNewswire
Dec-29	60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State SXTP -20.55% GlobeNewswire
Dec-11	60 Degrees Pharmaceuticals Announces Expansion of ARAKODA Sales and Marketing in 2026 SXTP -7.02% GlobeNewswire
Nov-21	60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine SXTP GlobeNewswire
Nov-13	60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results SXTP SXTP -22.22% GlobeNewswire
Oct-15	60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study SXTP -14.17% GlobeNewswire
Oct-09	60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study SXTP +5.48% GlobeNewswire
Sep-03	60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference SXTP GlobeNewswire
Aug-21	60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference SXTP GlobeNewswire
Aug-19	60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis SXTP GlobeNewswire
Aug-13	60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results SXTP GlobeNewswire
Jul-17	60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria SXTP -7.93% GlobeNewswire
Jul-16	60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering SXTP -6.29% GlobeNewswire
Jul-15	60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering SXTP -19.17% GlobeNewswire
Jul-15	60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion SXTP -19.17% GlobeNewswire
Jul-14	60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 SXTP -14.09% GlobeNewswire
Jun-04	60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA (tafenoquine) 8-Count Bottle Format SXTP GlobeNewswire
Jun-03	Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals SXTP GlobeNewswire
May-15	60 Degrees Pharmaceuticals Announces First Quarter 2025 Results SXTP SXTP +14.88% GlobeNewswire

Sixty Degrees Pharmaceuticals

Recent Articles by Sixty Degrees Pharmaceuticals

Upgrade your Finviz experience